Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00700102 · OUTCOME

Response Rate: Percentage of Participants With Best Overall Response, Defined as Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST Criteria

A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer. · Source last updated 2015-07-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
within 6.5 years

Analysis population: Participants with measurable disease

Groups in this outcome

Chemotherapy

Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal

Chemotherapy + Bevacizumab

Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Chemotherapy406
Chemotherapy + Bevacizumab404

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Chemotherapy3.9Not reported2.36.3Not reported
Chemotherapy + Bevacizumab5.4Not reported3.48.1Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    -1.5
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    4.5
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.3113
    param Type
    Mean Difference (Final Values)
    param Value
    1.50
    statistical Method
    Chi-squared
    tested Non Inferiority
    false
  2. ci Num Sides
    TWO_SIDED
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.4315
    statistical Method
    Cochran-Mantel-Haenszel
    tested Non Inferiority
    false
Complete source fields
analyses
  1. ci Lower Limit
    -1.5
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    4.5
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.3113
    param Type
    Mean Difference (Final Values)
    param Value
    1.50
    statistical Method
    Chi-squared
    tested Non Inferiority
    false
  2. ci Num Sides
    TWO_SIDED
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.4315
    statistical Method
    Cochran-Mantel-Haenszel
    tested Non Inferiority
    false
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2.3
        upper Limit
        6.3
        value
        3.9
      2. group Id
        OG001
        lower Limit
        3.4
        upper Limit
        8.1
        value
        5.4
denoms
  1. counts
    1. group Id
      OG000
      value
      406
    2. group Id
      OG001
      value
      404
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
    id
    OG000
    title
    Chemotherapy
  2. description
    Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
    id
    OG001
    title
    Chemotherapy + Bevacizumab
param Type
NUMBER
population Description
Participants with measurable disease
reporting Status
POSTED
time Frame
within 6.5 years
title
Response Rate: Percentage of Participants With Best Overall Response, Defined as Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST Criteria
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice